NPHC The CEO said that a company with a Phase 2 drug should have a $100 million dollar market value according to studies. He said based on their pipeline they should have a $30 million market value right now. This according to his spring interview.
This stock only has a market value of $2.4 million dollars right now based on my estimation of around 800 million shares outstanding and a .003 share price. NPHC is ridiculously undervalued at this level. The CEO said it should have a $30 million market value right now. That would put it around .04. Once phase 2 starts it should have a $100 million market value. That would put the share price at .13 per share based on 800 millions shares outstanding
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com or http://www.nyloxin.com http://www.petpainaway.com
Market Data 
Markets 
AI
